Assuming the COMPASS results are enough to convince regulators to make the low dose of rivaroxaban used in the study available to clinicians, the trial should influence how patients with stable ...

MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ — MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary artery ...

Dezeen shares the project of design student Ken Nakagaki, who has adapted a device to work with computer aided design (CAD) software to replicate digital files on paper. The device, named Comp*pass, ...

COMPASS-CAD started enrolling patients in November 2024 at Penn Medicine and has expanded to other sites. In COMPASS-CAD, patients classified as intermediate or borderline risk based on traditional ...